Zentalis Pharmaceuticals, Inc. Property, Plant and Equipment
Zentalis Pharmaceuticals, Inc. (ZNTL) had Property, Plant and Equipment of $2.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentNet · last filed 2026-08-06
- 2026-06-30: Property, Plant and Equipment, Net $2.50M.
- 2026-03-31: Property, Plant and Equipment, Net $2.65M.
- 2025-12-31: Property, Plant and Equipment, Net $2.77M.
- 2025-09-30: Property, Plant and Equipment, Net $2.93M.
| Period end | Property, Plant and Equipment, Net |
|---|---|
| 2026-06-30 | $2.50M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.77M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.93M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.09M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.25M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.70M 10-K · filed 2026-03-26 |
| 2024-09-30 | $5.02M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $5.34M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.68M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $5.82M 10-K · filed 2025-03-26 |
| 2023-09-30 | $6.39M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $6.65M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $6.88M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $7.71M 10-K · filed 2024-02-27 |
| 2022-09-30 | $8.03M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $8.22M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $8.48M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $8.15M 10-K · filed 2023-03-01 |
| 2021-09-30 | $4.70M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.25M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.51M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.10M 10-K · filed 2022-02-24 |
| 2020-09-30 | $471.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $481.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $519.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $501.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |